337 related articles for article (PubMed ID: 31391203)
1. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Wexler DJ; Krause-Steinrauf H; Crandall JP; Florez HJ; Hox SH; Kuhn A; Sood A; Underkofler C; Aroda VR;
Diabetes Care; 2019 Nov; 42(11):2098-2107. PubMed ID: 31391203
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Nathan DM; Buse JB; Kahn SE; Krause-Steinrauf H; Larkin ME; Staten M; Wexler D; Lachin JM;
Diabetes Care; 2013 Aug; 36(8):2254-61. PubMed ID: 23690531
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.
Sivitz WI; Phillips LS; Wexler DJ; Fortmann SP; Camp AW; Tiktin M; Perez M; Craig J; Hollander PA; Cherrington A; Aroda VR; Tan MH; Krakoff J; Rasouli N; Butera NM; Younes N;
Diabetes Care; 2020 May; 43(5):940-947. PubMed ID: 32139384
[TBL] [Abstract][Full Text] [Related]
4. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Gonzalez JS; Bebu I; Krause-Steinrauf H; Hoogendoorn CJ; Crespo-Ramos G; Presley C; Naik AD; Kuo S; Johnson ML; Wexler D; Crandall JP; Bantle AE; Arends V; Cherrington AL;
Diabetes Care; 2024 Apr; 47(4):610-619. PubMed ID: 38416773
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
7. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
Deng Y; Polley EC; Wallach JD; Dhruva SS; Herrin J; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Lyon TD; Shah ND; Ross JS; McCoy RG
BMJ; 2022 Oct; 379():e070717. PubMed ID: 36191949
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Wexler DJ; de Boer IH; Ghosh A; Younes N; Bebu I; Inzucchi SE; McGill JB; Mudaliar S; Schade D; Steffes MW; Tamborlane WV; Tan MH; Ismail-Beigi F;
JAMA Intern Med; 2023 Jul; 183(7):705-714. PubMed ID: 37213109
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Kirkman MS; Tripputi M; Krause-Steinrauf H; Bebu I; AbouAssi H; Burch H; Duran-Valdez E; Florez H; Garvey WT; Hsia DS; Salam M; Pop-Busui R;
Diabetes Care; 2024 Apr; 47(4):594-602. PubMed ID: 38194519
[TBL] [Abstract][Full Text] [Related]
12. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Amin NB; Aggarwal N; Pall D; Paragh G; Denney WS; Le V; Riggs M; Calle RA
Diabetes Obes Metab; 2015 Aug; 17(8):751-9. PubMed ID: 25885172
[TBL] [Abstract][Full Text] [Related]
13. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
; Nathan DM; Lachin JM; Bebu I; Burch HB; Buse JB; Cherrington AL; Fortmann SP; Green JB; Kahn SE; Kirkman MS; Krause-Steinrauf H; Larkin ME; Phillips LS; Pop-Busui R; Steffes M; Tiktin M; Tripputi M; Wexler DJ; Younes N
N Engl J Med; 2022 Sep; 387(12):1075-1088. PubMed ID: 36129997
[TBL] [Abstract][Full Text] [Related]
14. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
[TBL] [Abstract][Full Text] [Related]
15. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
16. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
[TBL] [Abstract][Full Text] [Related]
18. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Tang A; Rabasa-Lhoret R; Castel H; Wartelle-Bladou C; Gilbert G; Massicotte-Tisluck K; Chartrand G; Olivié D; Julien AS; de Guise J; Soulez G; Chiasson JL
Diabetes Care; 2015 Jul; 38(7):1339-46. PubMed ID: 25813773
[TBL] [Abstract][Full Text] [Related]
19. The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Hollander PA; Krause-Steinrauf H; Butera NM; Kazemi EJ; Ahmann AJ; Fattaleh BN; Johnson ML; Killean T; Lagari VS; Larkin ME; Legowski EA; Rasouli N; Willis HJ; Martin CL;
Diabetes Care; 2024 Apr; 47(4):638-645. PubMed ID: 37756542
[TBL] [Abstract][Full Text] [Related]
20. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
